Oral Semaglutide Reduced Heavy Drinking and Alcohol Craving in Clinical Trial
A randomized clinical trial published in the American Journal of Psychiatry found that oral semaglutide, a medication originally developed for diabetes and weight management, reduced heavy drinking days, alcohol craving, and alcohol-related problems among treatment-seeking adults with alcohol use disorder.
What the Study Found
Researchers randomly assigned adults with alcohol use disorder who were seeking treatment to receive either oral semaglutide or a placebo, in addition to standard care. Participants taking semaglutide reported fewer heavy drinking days, lower self-reported craving for alcohol, and fewer alcohol-related problems over the course of the trial compared to those taking placebo.
Why This Is Being Studied
Semaglutide belongs to a class of medications called GLP-1 receptor agonists, which act on brain circuits involved in reward and appetite regulation. Researchers have become interested in whether these same reward pathways, which appear to reduce food cravings, might also reduce cravings for alcohol and other substances, an area sometimes described as overlapping addictive-behavior circuitry.
What This Research Does Not Prove
This is a single clinical trial, and semaglutide is not currently approved by regulators specifically for treating alcohol use disorder. The results need to be replicated in larger and longer trials before this could become a standard, approved treatment option. It also remains unclear which patients might benefit most, and what the long-term safety profile looks like when the medication is used specifically for this purpose.
Which Professional to See
Alcohol use disorder is typically evaluated and treated by a primary care physician, addiction medicine specialist, or psychiatrist, often alongside counseling or structured treatment programs. Anyone considering a medication for alcohol use disorder, including existing approved options, should discuss this with a prescribing clinician.
Questions to Ask
Useful questions include: What treatment options, including medication and behavioral therapy, are currently approved and available for alcohol use disorder? Are there clinical trials in my area studying newer medication approaches? What are the risks and benefits of the treatments already available to me right now?
Bottom Line
Early clinical trial results suggest oral semaglutide may help reduce heavy drinking and alcohol craving, adding to interest in GLP-1 medications beyond diabetes and weight management. This is not yet an approved or standard treatment for alcohol use disorder, and current evidence-based treatments remain the appropriate starting point for care.
Related Topics
Related reading: Alcohol Use Disorder
This article is for informational purposes only and does not constitute medical advice. If you or someone you know is experiencing a mental health crisis, please contact a licensed healthcare provider or local emergency services.